Zimmer Biomet Intrinsic Stock Value – Advisor Group Holdings Increases Investment in Zimmer Biomet, Analysts Debate Future Outlook

🌥️Trending News

Zimmer Biomet ($NYSE:ZBH), one of the world’s leading medical device companies, has received a major investment boost from Advisor Group Holdings Inc. The company’s recent 13F filing with the Securities & Exchange Commission reveals that Advisor Group Holdings Inc. has increased its stake in Zimmer Biomet, but analysts are split on the company’s future prospects. Zimmer Biomet is a global leader in musculoskeletal health solutions. Its portfolio of innovative products and services includes joint replacement products, braces and supports, sports medicine, trauma and extremities solutions, office-based technologies, spine, craniomaxillofacial and thoracic solutions, and dental implants. As a result, Zimmer Biomet serves a wide range of customers including orthopedic surgeons, orthopedic trauma surgeons, physical therapists, chiropractors, podiatrists, spine surgeons, neurologists and dentists. Despite the recent capital injection from Advisor Group Holdings Inc., analysts are divided on the future prospects of Zimmer Biomet.

Some believe that the company’s strong portfolio of innovative products will help it gain market share in a competitive industry. Others, however, point to the increasing competition in the medical device market and warn that Zimmer Biomet’s margins may be squeezed as rivals battle for customers. Only time will tell whether Zimmer Biomet is able to capitalize on its recent financial boost and maintain its position as a leader in musculoskeletal health solutions. For now, investors will be closely monitoring the company’s performance to gauge its future prospects.

Price History

The news sent Zimmer Biomet‘s stock up by nearly 0.5%, with shares opening at $130.0 and closing at $130.5. This was an increase from the prior closing price of $129.8. Some believe that the company has potential to continue to grow in the coming years, while others are more skeptical, citing the increasingly competitive medical device industry as a potential obstacle. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Zimmer Biomet. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Zimmer Biomet. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Zimmer Biomet. More…

Key Ratios Snapshot

Some of the financial key ratios for Zimmer Biomet are shown below. More…

Analysis – Zimmer Biomet Intrinsic Stock Value

GoodWhale has conducted an analysis of ZIMMER BIOMET‘s fundamentals and have concluded that the fair value of ZIMMER BIOMET share is around $130.0, calculated by our proprietary Valuation Line. Currently, ZIMMER BIOMET stock is traded at $130.5, which is a fair price. We believe that it is an attractive price for long term investors who are looking to add value to their portfolio. We have taken into consideration many factors such as company performance, financials, dividend history, future outlook and industry trends before arriving at this fair value. We are confident that investors will benefit from our research and make smart decisions with the provided information. More…

Peers

The company operates in two segments, Reconstructive and Dental. It offers knee, hip, shoulder, elbow, hand and wrist, foot and ankle, and biologics products. The company also provides dental prosthetics, including dental implants and CAD/CAM systems; and digital equipment for dentists and laboratories. Zimmer Biomet has a market cap of $24.4 billion and is headquartered in Warsaw, Indiana.

– Alcon Inc ($LTS:0A0D)

Alcon Inc is a global medical company that specializes in eye care products and services. The company’s market cap as of 2022 is 30.09B, and its return on equity is 1.87%. Alcon’s products and services include contact lenses, intraocular lenses, ophthalmic surgical devices, and ophthalmic pharmaceuticals. The company has a presence in over 100 countries and serves customers in the retail, wholesale, and government sectors.

– Sonova Holding AG ($LTS:0QPY)

Sonova Holding AG is a Swiss manufacturer of hearing aids. The company was founded in 1947 and is headquartered in Zurich, Switzerland. As of 2020, Sonova Holding AG had a market cap of 15.37 billion Swiss francs and a return on equity of 18.9%. The company’s products are sold under the brand names Phonak, Unitron, and Advanced Bionics. Sonova Holding AG’s products are available in more than 100 countries.

– Tandem Diabetes Care Inc ($NASDAQ:TNDM)

Tandem Diabetes Care Inc is a medical device company that develops, manufactures and sells insulin pumps for people with diabetes. The company has a market cap of $2.56 billion and a return on equity of -8.79%. Tandem’s products include the t:slim X2 insulin pump, the t:flex insulin pump, and the t:slim G4 insulin pump. The company also offers the t:lock Connectivity System, a cloud-based software platform that allows users to manage their diabetes devices and data.

Summary

Advisor Group Holdings Inc. has increased its ownership in Zimmer Biomet, a medical device company that designs, manufactures, and markets orthopaedic reconstructive products, spinal products, and other related products worldwide. Despite this, analysts remain divided on the future prospects of Zimmer Biomet. Investors should take into account the opinions of both sides before making any decisions. They should also consider current market conditions and any potential risks before investing.

Additionally, research on the company’s financials and reputation can help investors make an informed decision.